ClinicalTrials.gg
CompletedNCT07399470Updated Jul 24, 2026

A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.

A Phase 1 interventional study of Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg and Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg in Healthy Volunteers and Fasting Conditions, sponsored by LG Chem. Completed at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by LG Chem · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

Bioequivalence study for the fixed-dose combination of Gemigliptin/Dapagliflozin/Metformin 50/10/1000 mg under fasting conditions in healthy volunteers

02

Conditions studied

  • Healthy Volunteers
  • Fasting Conditions

Keywords

  • Fasting conditions
  • Healthy Volunteers
  • Bioequivalence Study
03

In context

Lead sponsor

LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults between 19 and 50 years of age
  • People with a body weight within a healthy range
  • People who do not have serious medical conditions and have been generally healthy in recent years
  • People whose screening tests (blood tests, urine tests, vital signs, , etc.) show no significant abnormalities
  • Women of must not be pregnant at screening
  • Participants must agree to use reliable or abstain from sexual activity during the study and for a short period after the last dose
  • People who fully understand the study, agree to follow study requirements, and provide written

Exclusion criteria

Exclusion Criteria:

  • People with a history of significant diseases, such as heart, liver, kidney, lung, neurological, psychiatric, immune, or cancer-related conditions
  • People with digestive diseases or surgeries that may affect how medicines are absorbed
  • People with abnormal screening laboratory results, especially related to liver or kidney function
  • People who drink large amounts of alcohol, use drugs, or smoke heavily
  • People who have recently taken certain medications, herbal products, or dietary supplements that could interfere with the study
  • People who have recently participated in another clinical trial, donated blood, or received a blood transfusion
  • Pregnant or breastfeeding women
  • People with unstable or serious health conditions that could increase risk or affect study results
  • Anyone who, in the opinion of the study doctor, is not suitable to participate
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Sequence 1

    test drug \> reference drug

    Drug: Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg · Drug: Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg

  • Experimental
    Sequence 2

    reference drug \> test drug

    Drug: Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg · Drug: Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg

Interventions

  • DrugTest drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg

    All participants will take 1 tablet of either test drug or 2 tablets of reference drug with fasting conditions.

  • DrugReference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg

    Drug page: Gemigliptin

    All participants will take 1 tablet of either test drug or 2 tablest of reference drug with fasting conditions.

06

What researchers measure

Primary outcomes

  1. The plasma concentration of Gemigliptin, Dapagliflozin and Metformin

    Area under the plasma concentration versus time curve (AUClast) of Gemigliptin, Dapagliflozin, and Metformin

    Time frame: Up to 72 hours

  2. The plasma concentration of Gemigliptin, Dapagliflozin and Metformin

    Peak Plasma Concentration (Cmax) of Gemigliptin, Dapagliflozin, and Metformin

    Time frame: Up to 72 hours

Secondary outcomes

  1. The plasma concentration of Gemigliptin, Dapagliflozin and Metformin.

    Time to Maximum Concentration(Tmax) of Gemigliptin, Dapagliflozin, and Metformin

    Time frame: Up to 72 hours

  2. The plasma concentration of Gemigliptin, Dapagliflozin and Metformin

    Lag Time(Tlag) of Gemigliptin, Dapagliflozin, and Metformin

    Time frame: Up to 72 hours

  3. The plasma concentration of Gemigliptin, Dapagliflozin and Metformin

    Area Under the Curve to Infinity(AUCinf) of Gemigliptin, Dapagliflozin, and Metformin

    Time frame: Up to 72 hours

  4. The plasma concentration of Gemigliptin, Dapagliflozin and Metformin

    Half-life(t1/2) of Gemigliptin, Dapagliflozin, and Metformin

    Time frame: Up to 72 hours

  5. The plasma concentration of Gemigliptin, Dapagliflozin and Metformin

    Apparent Clearance(CL/F) of Gemigliptin, Dapagliflozin, and Metformin

    Time frame: Up to 72 hours

07

Study locations

1 site
  • Jeonbuk National University Hospital
    Jeonju, Jeollabuk-do 54907, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Feb 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Feb 10, 2026
StartActual
Jan 9, 2026
Primary completionActual
Feb 6, 2026
CompletionActual
Feb 6, 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07399470
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Jan 9, 2026
Primary completion
Feb 6, 2026
Completion
Feb 6, 2026
Last update
Jul 24, 2026

Study contacts

Seol Ju Moon, M.D., Professor
principal investigator · Jeonbuk National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemigliptin

Start the discussion